Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck (MRK) announced on Wednesday that its single-tablet antiviral regimen, doravirine and islatravir for adults with HIV, ...

Researchers at Johns Hopkins Medicine, in collaboration with researchers at the National Institutes of Health, report that two new studies in mice with a humanized immune system and human cell lines ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...

New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...

An early trial for an experimental HIV vaccine candidate has shown promising results. 97% of recipients in a phase 1 study showed immune system activity in response to the vaccine. But there's a long ...

Long-term (24-month) supplementation with multivitamins plus selenium for human immunodeficiency virus (HIV)-infected patients in Botswana in the early stages of disease who had not received ...

Informal Providers—Ground Realities in South Asian Association for Regional Cooperation Nations: Toward Better Cancer Primary Care: A Narrative Review Hidden oral cancer sites and residence in ...

The vaccine candidate didn't lower the risk of HIV infection among participants. In yet another setback in the decadeslong scientific quest for an HIV vaccine, a Johnson & Johnson HIV vaccine ...

Please provide your email address to receive an email when new articles are posted on . HIV and menopausal stage are both independent predictors of lower bone mineral density in women, particularly in ...